![Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study | Journal of the American Heart Association Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/5c94cb12-8c4c-48fe-aaca-badd96a0fbaa/jah31709-fig-0002.gif)
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study | Journal of the American Heart Association
![Belgian data of ODYSSEY APPRISE: stringent LDL‐c targets are in reach when using all available tools - Verdickt - - International Journal of Clinical Practice - Wiley Online Library Belgian data of ODYSSEY APPRISE: stringent LDL‐c targets are in reach when using all available tools - Verdickt - - International Journal of Clinical Practice - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/89626e0f-717c-4c63-97bf-bc3cde25e0c6/ijcp14916-fig-0001-m.jpg)
Belgian data of ODYSSEY APPRISE: stringent LDL‐c targets are in reach when using all available tools - Verdickt - - International Journal of Clinical Practice - Wiley Online Library
![ALIROCUMAB : MECHANISM OF ACTION, PHARMACOKINETICS, SAFETY, AND CLINICAL OUTCOMES | Pharmaceutical Journal of Indonesia ALIROCUMAB : MECHANISM OF ACTION, PHARMACOKINETICS, SAFETY, AND CLINICAL OUTCOMES | Pharmaceutical Journal of Indonesia](https://pji.ub.ac.id/public/journals/1/cover_issue_7_en_US.jpg)
ALIROCUMAB : MECHANISM OF ACTION, PHARMACOKINETICS, SAFETY, AND CLINICAL OUTCOMES | Pharmaceutical Journal of Indonesia
![JCM | Free Full-Text | Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy | HTML JCM | Free Full-Text | Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy | HTML](https://www.mdpi.com/jcm/jcm-10-02968/article_deploy/html/images/jcm-10-02968-g001.png)
JCM | Free Full-Text | Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy | HTML
![PCSK9 inhibitors mechanism of action. (A) PCSK9 is primarily secreted... | Download Scientific Diagram PCSK9 inhibitors mechanism of action. (A) PCSK9 is primarily secreted... | Download Scientific Diagram](https://www.researchgate.net/publication/335918960/figure/fig1/AS:804832348733440@1568898393460/PCSK9-inhibitors-mechanism-of-action-A-PCSK9-is-primarily-secreted-in-the-liver-and.png)
PCSK9 inhibitors mechanism of action. (A) PCSK9 is primarily secreted... | Download Scientific Diagram
![Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study | Lipids in Health and Disease | Full Text Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study | Lipids in Health and Disease | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12944-017-0493-7/MediaObjects/12944_2017_493_Fig2_HTML.gif)
Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study | Lipids in Health and Disease | Full Text
![Frontiers | Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders | Neuroscience Frontiers | Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders | Neuroscience](https://www.frontiersin.org/files/Articles/548891/fnins-14-00609-HTML/image_m/fnins-14-00609-g001.jpg)